MA53543A - Vaccins peptidiques - Google Patents

Vaccins peptidiques

Info

Publication number
MA53543A
MA53543A MA053543A MA53543A MA53543A MA 53543 A MA53543 A MA 53543A MA 053543 A MA053543 A MA 053543A MA 53543 A MA53543 A MA 53543A MA 53543 A MA53543 A MA 53543A
Authority
MA
Morocco
Prior art keywords
peptide vaccines
vaccines
peptide
Prior art date
Application number
MA053543A
Other languages
English (en)
Inventor
Zsolt Csiszovszk
Julianna Liszewicz
Orsolya Lorincz
Mónika Megyesi
Levente Molnar
Katalin Pantya
Eszter Somogyi
Eniko Toke
József Toth
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1814365.1A external-priority patent/GB201814365D0/en
Priority claimed from GBGB1814364.4A external-priority patent/GB201814364D0/en
Priority claimed from GBGB1814367.7A external-priority patent/GB201814367D0/en
Priority claimed from GBGB1814366.9A external-priority patent/GB201814366D0/en
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of MA53543A publication Critical patent/MA53543A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
MA053543A 2018-09-04 2019-09-03 Vaccins peptidiques MA53543A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1814365.1A GB201814365D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814364.4A GB201814364D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814367.7A GB201814367D0 (en) 2018-09-04 2018-09-04 Peptide Vaccines
GBGB1814366.9A GB201814366D0 (en) 2018-09-04 2018-09-04 Peptide vaccines

Publications (1)

Publication Number Publication Date
MA53543A true MA53543A (fr) 2021-07-14

Family

ID=67874441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053543A MA53543A (fr) 2018-09-04 2019-09-03 Vaccins peptidiques

Country Status (16)

Country Link
US (2) US11666644B2 (fr)
EP (1) EP3846845A1 (fr)
JP (2) JP7642530B2 (fr)
KR (1) KR20210086612A (fr)
CN (1) CN113329761A (fr)
AU (1) AU2019334437A1 (fr)
BR (1) BR112021004071A2 (fr)
CA (1) CA3110760A1 (fr)
CL (2) CL2021000532A1 (fr)
CO (1) CO2021004019A2 (fr)
IL (1) IL281224A (fr)
MA (1) MA53543A (fr)
MX (1) MX2021002449A (fr)
SA (1) SA521421371B1 (fr)
SG (1) SG11202101888YA (fr)
WO (1) WO2020048990A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110651189B (zh) 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
MX2021015765A (es) * 2019-06-28 2022-01-27 The Francis Crick Institute Ltd Nuevos antigenos y metodos contra el cancer.
EP4175664A2 (fr) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
WO2022233956A1 (fr) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant de manière spécifique à prame
KR102846816B1 (ko) * 2023-06-28 2025-08-18 주식회사 이온셀 Ct83 항원에 대한 인간 단클론 항체 및 이의 용도
CN119751578A (zh) * 2025-03-10 2025-04-04 南昌大学第一附属医院 结直肠癌新抗原免疫多肽及其应用

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
CN1225590A (zh) 1996-03-11 1999-08-11 埃皮曼尼公司 对hla分子结合亲和力提高的肽
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
AU768834B2 (en) 1998-04-01 2004-01-08 Yale University A method for selectively modulating the interactions between survivin and tubulin
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
JP2003517310A (ja) * 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003270311A1 (en) 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
WO2005049073A2 (fr) 2003-11-19 2005-06-02 Survac Aps Proteines appartenant a la famille bcl-2, fragments associes, et utilisation therapeutique de ces proteines et fragments sur des patients atteints du cancer
CN1910284B (zh) 2004-01-20 2011-04-06 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
CA2566506A1 (fr) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides destines a induire une reponse ctl et/ou htl au virus de l'hepatite c
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
EP1842911A4 (fr) 2005-01-25 2008-12-10 Nec Corp Peptides se liant au hla, fragments d'adn codant pour lesdits peptides et vecteurs recombinants
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
CN100402554C (zh) 2005-02-25 2008-07-16 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
CA2643337C (fr) 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Traitement du cancer associant un agent lymphodepleteur a des ctl et des cytokines
WO2008035350A1 (fr) 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Vaccins à multiples épitopes spécifiques à un antigène
CA2700573C (fr) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
JP5543207B2 (ja) 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
WO2008116468A2 (fr) 2007-03-26 2008-10-02 Dako Denmark A/S Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses
EP2042600A1 (fr) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique Epitope de cellule CD4+ T publique et immunogène de la protéine tat vih et ses applications
KR101648146B1 (ko) * 2008-03-31 2016-08-16 텔라 가부시키가이샤 Ｍｈｃ 클래스 ⅱ 분자에 제시되는 서바이빈의 부분 펩타이드 및 그의 용도
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (fr) 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
US20120244145A1 (en) 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (fr) 2010-10-14 2012-04-19 The Ohio State University Research Foundation Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l)
BR112013023978B1 (pt) 2011-03-21 2021-09-08 Atlantic Cancer Research Institute Polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica
WO2012141201A1 (fr) * 2011-04-11 2012-10-18 公立大学法人大阪市立大学 Peptide pour l'immunothérapie du cancer et procédé d'utilisation de celui-ci
CN102973950B (zh) * 2011-09-06 2015-05-27 四川百利药业有限责任公司 Prame、wt1双价肿瘤dna疫苗
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
US20140234350A1 (en) 2013-02-14 2014-08-21 Cedars-Sinai Medical Center Ovarian cancer vaccines and vaccination methods
CA2908042C (fr) 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Methode d'amelioration de l'efficacite d'un vaccin a base de survivine pour le traitement du cancer
EP2983702A2 (fr) * 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions et procédés s'appliquant à des vaccins personnalisés contre les néoplasies
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015143335A1 (fr) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Méthodes et compositions pour protéines spike de coronavirus chimère
WO2015164798A1 (fr) 2014-04-25 2015-10-29 Tria Bioscience Corp. Compositions de support d'haptène synthétique et procédés
WO2016040900A1 (fr) 2014-09-14 2016-03-17 Washington University Vaccins anticancéreux personnalisés, et procédés correspondants
US20160074489A1 (en) 2014-09-15 2016-03-17 Regen Biopharma, Inc Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation
US10317402B2 (en) * 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
EP3242883A4 (fr) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Mimétiques de lipide a, procédés de préparation, et leurs utilisations
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
JP6851983B2 (ja) 2015-05-01 2021-03-31 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
IL255722B2 (en) * 2015-06-29 2024-05-01 Ose Immunotherapeutics A method for inducing an early memory response with an anticancer vaccine of short peptides
HK1255161A1 (zh) 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
US9790562B2 (en) 2015-09-30 2017-10-17 Augusta University Research Institute, Inc. Compositions and methods for the detection or treatment of uterine leiomyosarcoma
CA3003251A1 (fr) 2015-10-12 2017-04-20 Nantomics, Llc Systemes, compositions, et procedes de decouverte de msi et de neoepitopes qui prevoient la sensibilite a des points de controle immunitaires
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
WO2017083963A1 (fr) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Systèmes adjuvant et compositions vaccinales sans eau comprenant un adjuvant de type polyi:c et un adjuvant lipidique
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
EP3455630A4 (fr) 2016-05-13 2020-01-08 MBL International Corp. Système et procédé d'échange de peptides
JP2020503840A (ja) * 2016-10-07 2020-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用
WO2018102585A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes
WO2018138257A1 (fr) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EP3369431A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Vaccin
CN110651189B (zh) 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
EP3370065A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Peptides immunogènes
WO2019010560A1 (fr) 2017-07-10 2019-01-17 Immmunovaccine Technologies Inc. Compositions pharmaceutiques, procédés de préparation utilisant des particules de vésicules lipidiques de taille définie, et leurs utilisations
AU2018366131A1 (en) 2017-11-08 2020-05-28 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
AU2017438994A1 (en) 2017-11-09 2020-05-28 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
EP3731876A4 (fr) 2017-12-28 2022-04-06 Gritstone bio, Inc. Protéines se liant à l'antigène ciblant des antigènes partagés
US20210213066A1 (en) 2018-05-18 2021-07-15 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
JP2021526365A (ja) 2018-05-18 2021-10-07 チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 改善された標的化ｔ細胞療法
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
US20220125903A1 (en) 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
WO2020146434A2 (fr) 2019-01-07 2020-07-16 Children's National Medical Center Compositions de lymphocytes t activées ex vivo et leurs procédés d'utilisation
CA3126064A1 (fr) 2019-01-07 2020-07-16 Children's National Medical Center Therapie amelioree a lymphocytes t cibles pour le traitement du myelome multiple
CN114727957A (zh) 2019-10-16 2022-07-08 免疫疫苗技术公司 用于递送活性剂或治疗剂的水包油乳剂制剂
CN110713546B (zh) 2019-10-31 2021-04-20 中国医科大学附属第一医院 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Also Published As

Publication number Publication date
JP2021536487A (ja) 2021-12-27
BR112021004071A2 (pt) 2021-06-01
AU2019334437A1 (en) 2021-03-18
JP2024097033A (ja) 2024-07-17
JP7642530B2 (ja) 2025-03-10
IL281224A (en) 2021-04-29
CA3110760A1 (fr) 2020-03-12
US11666644B2 (en) 2023-06-06
SG11202101888YA (en) 2021-03-30
CN113329761A (zh) 2021-08-31
SA521421371B1 (ar) 2024-06-06
CL2024001738A1 (es) 2024-11-15
CO2021004019A2 (es) 2021-07-19
US20230102031A1 (en) 2023-03-30
US20240000911A1 (en) 2024-01-04
KR20210086612A (ko) 2021-07-08
EP3846845A1 (fr) 2021-07-14
MX2021002449A (es) 2021-08-05
CL2021000532A1 (es) 2021-09-24
WO2020048990A1 (fr) 2020-03-12

Similar Documents

Publication Publication Date Title
MA47677A (fr) Vaccins peptidiques
IL284348A (en) Hiv pre-immunization and immunotherapy
PL3727460T3 (pl) Bicykliczne ligandy peptydowe swoiste wobec epha2
MA53543A (fr) Vaccins peptidiques
IL263846B (en) Formulation of a peptide vaccine
DK3609535T3 (da) Hbv-vaccine
DK3723783T3 (da) Mitokondrie-målrettede peptider
DK3393505T3 (da) Rekombinante zika-vacciner
EP3700565A4 (fr) Vaccins avec adjuvant
EP3773649A4 (fr) Vaccins anticancéreux personnalisés
HUE053347T2 (hu) Glikopeptid-készítmények
EP3603619A4 (fr) Formulation d'adjuvant vaccinal
MA52011A (fr) Vaccins peptidiques contre l'interleukine-31
HUE055762T2 (hu) Nyújtott hatású készítmények
MA52180A (fr) Vaccins thérapeutiques anti-abêta
EP3560512A4 (fr) Composition de vaccin contre le zona
EP3743084A4 (fr) Vaccins antiviraux recombinants
DK3826600T3 (da) Isforet vaccinekøleskab
LT3522905T (lt) Imunogeniniai arginazės peptidai
PL3709970T3 (pl) Preparaty linezolidu
EP3638297A4 (fr) Vaccin bactérien
EP3765067C0 (fr) Vaccins autologues contre le cancer
DK3274447T3 (da) Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine
EP3528843A4 (fr) Vaccins anti-opioïdes
EP3518957C0 (fr) Protéine thérapeutique